| 杨昀山,金相任,唐云川,等.CLDN18.2作为靶向治疗的新靶点在胃癌中的研究进展[J].安徽医药,2025,29(10):1934-1939. |
| CLDN18.2作为靶向治疗的新靶点在胃癌中的研究进展 |
| Research progress of CLDN18.2 as a new target of targeted therapy on gastric cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2025.10.005 |
| 中文关键词: 紧密连接蛋白质类 胃肿瘤 抗体，单克隆 嵌合抗原受体 免疫疗法 靶向治疗 精准治疗 综述 |
| 英文关键词: Tight junction proteins Stomach neoplasms Antibodies,monoclonal Chimeric antigen receptor Immunotherapy Targeted therapy Personalized medicine Review |
| 基金项目: |
|
| 摘要点击次数: 38 |
| 全文下载次数: 45 |
| 中文摘要: |
| 紧密连接蛋白 18.2(Claudin18.2，CLDN18.2)属于紧密连接蛋白家族成员 CLDN18的一个亚型，是一种高度选择性的标记蛋白，参与肿瘤细胞的增殖、分化和转移，在多种恶性肿瘤发生发展过程中发现异常表达，并展现了一定的靶向治疗的潜力。尤其是在胃癌中， CLDN18.2可能成为继 HER-2之后新的潜在治疗靶点。针对 CLDN18.2开发的靶向药物的相关临床试验还处于早期阶段，但已取得了令人振奋的结果，该研究综述了与 CLDN18.2相关的最新研究进展，包括单克隆抗体、双特异性抗体、 CAR-T细胞和抗体 -药物偶联物，探讨 CLDN18.2阳性胃癌综合治疗的新方向。 |
| 英文摘要: |
| CLDN18.2 (Claudin18.2) is a subtype of Claudin18, a member of the tight junction protein family. It is a highly selectivemarker protein that is intricately involved in tumor cell proliferation, differentiation, and migration. Aberrant expression of CLDN18.2has been observed during the development of various malignant tumors, thus unveiling its potential for targeted therapeutic interven-tions. Notably, within the context of gastric cancer, CLDN18.2 emerges as a novel potential therapeutic target, second only to HER-2. Although clinical trials targeting CLDN18.2 are in their preliminary stages, the outcomes have been remarkably promising. This com-prehensive review encapsulates the latest advancements linked to CLDN18.2, encompassing monoclonal antibodies, bispecific antibod-ies, CAR-T cells, and antibody-drug conjugates. Moreover, the review discusses the novel trajectory for the integrated treatment of CLDN18.2-positive gastric cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
